Kyverna Therapeutics Financials

No, Kyverna Therapeutics (KYTX) reported a net income of -$161.3M in fiscal year 2025.

Kyverna Therapeutics (KYTX) reported diluted earnings per share of $-3.64 for fiscal year 2025. This represents a -9.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kyverna Therapeutics (KYTX) had EBITDA of -$168.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Kyverna Therapeutics (KYTX) has a return on equity of -69.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Kyverna Therapeutics (KYTX) generated -$153.7M in free cash flow during fiscal year 2025. This represents a -32.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Kyverna Therapeutics (KYTX) generated -$153.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Kyverna Therapeutics (KYTX) had $293.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Kyverna Therapeutics (KYTX) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Kyverna Therapeutics (KYTX) invested $133.7M in research and development during fiscal year 2025.

Kyverna Therapeutics (KYTX) had 60M shares outstanding as of fiscal year 2025.

Kyverna Therapeutics (KYTX) had a current ratio of 7.75 as of fiscal year 2025, which is generally considered healthy.

Kyverna Therapeutics (KYTX) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Kyverna Therapeutics (KYTX) had a return on assets of -54.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Kyverna Therapeutics (KYTX) had $124.1M in cash against an annual operating cash burn of $153.7M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Kyverna Therapeutics (KYTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Kyverna Therapeutics (KYTX) has an earnings quality ratio of 0.95x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Kyverna Therapeutics (KYTX) has an interest coverage ratio of -424.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.